KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Income from Continuing Operations (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Income from Continuing Operations data on record, last reported at 153638000.0 in Q2 2025.

  • For Q2 2025, Income from Continuing Operations rose 2272.05% year-over-year to 153638000.0; the TTM value through Jun 2025 reached 260401000.0, down 8.94%, while the annual FY2024 figure was 142882000.0, 148.06% up from the prior year.
  • Income from Continuing Operations reached 153638000.0 in Q2 2025 per SRPT's latest filing, up from 66651000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 329335000.0 in Q4 2022 and bottomed at 516755000.0 in Q1 2023.
  • Average Income from Continuing Operations over 5 years is 40263882.35, with a median of 40937000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: crashed 856.15% in 2021, then skyrocketed 2272.05% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 121981000.0 in 2021, then skyrocketed by 369.99% to 329335000.0 in 2022, then fell by 13.67% to 284315000.0 in 2023, then tumbled by 76.56% to 66651000.0 in 2024, then surged by 130.51% to 153638000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 153638000.0 in Q2 2025, 66651000.0 in Q4 2024, and 33635000.0 in Q3 2024.